|Bid||84.07 x 1000|
|Ask||84.09 x 900|
|Day's Range||84.02 - 84.20|
|52 Week Range||16.69 - 84.48|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 25, 2020 - Mar. 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.55|
WILMINGTON, Del., Dec. 10, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Audentes Therapeutics, Inc. (NASDAQ GS: BOLD) regarding possible breaches of.
BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of The Medicines Company ("TMC" or "the Company") (MDCO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Novartis AG. Under the terms of the agreement, TMC shareholders will receive only $85.00 for each share of TMC common stock owned. The investigation concerns whether the TMC Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Novartis is underpaying for the Company.
NEW YORK, Dec. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ: MDCO)The.
NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
NEW YORK, NY / ACCESSWIRE / DECEMBER 5, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
NEW YORK, Dec. 04, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: TD Ameritrade Holding Corporation (NASDAQ:.
WILMINGTON, Del., Dec. 03, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: The Medicines Company (NASDAQ GS: MDCO) regarding possible breaches of.
NEW YORK, NY / ACCESSWIRE / December 2, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
(Bloomberg Opinion) -- Drugmakers have spent years de-emphasizing heart medications in favor of higher-priced treatments for cancer and rare diseases. As America enters its most caloric season, it looks like that is starting to change, for now. Novartis AG made a particularly large commitment Sunday with its $9.7 billion purchase of Medicines Co. and its promising new cholesterol drug. Meanwhile, biotechnology company Amarin Corp.’s bet on its fish-oil-derived capsule Vascepa is starting to pay off: Its shares soared earlier this month after a Food and Drug Administration panel recently suggested the pill — which was shown to cut cardiac risk in a huge trial last year — be made available to millions of additional patients. Heart medicines are also key pipeline components or sales drivers at a number of big pharmaceutical companies as well, from Merck & Co. and Bayer AG to Pfizer Inc.Investment in cardiac medicines is positive for patients and public health; after all, heart disease remains the most significant cause of death in the U.S. There’s a reason that drugmakers had backed away, however. These companies will have to navigate a harsh market environment to keep this mini-renaissance alive. Effective heart disease medicines, including statins for cholesterol and drugs for high blood pressure, have become much cheaper as generic options have hit the market. That’s excellent for patients and health budgets, as expanded use of these drugs has been impactful enough to slow Medicare spending growth. But it makes things difficult for newer, higher-priced medicines to make inroads. Next-generation drugs need to prove they can add something on top of or substantially outperform cheaper options to have a chance at anything but niche success. They sometimes still struggle even if they do. Cardiovascular drugs take time to have an impact, and the American health-care system isn’t patient. People change health insurance all the time as they swap or lose jobs, pick a new plan, or have one selected for them. Health plans often focus on annual costs and don’t always want to pay extra for an uncertain benefit that might eventually save someone else money. That tendency is most pronounced in large markets, where rapid uptake of a new drug translates into substantial spending increases.Two relatively new cholesterol drugs — Praluent, from Sanofi and Regeneron Pharmaceutical Co., and Amgen Inc.’s Repatha — are the most significant recent cautionary tales. They were both approved in 2015 with high expectations and are effective medications, but the market balked at their high price and threw up barriers to access. The result was a glacial launch. Sales remain sluggish even after major price cuts. Medicine Co.’s inclisiran lowers cholesterol at a similar rate by using the same drug target as those medicines but requires far less frequent dosing. Novartis will have to find out whether convenience is enough to command a premium price and avoid the same commercial fate. As for Amarin, a drug-price watchdog called Vascepa a rare cost-effective option for heart disease earlier this year. That doesn’t guarantee a rapid ascent to blockbuster sales. The drug’s future is partially in the FDA’s hands. The exact language of the agency’s expanded approval will help determine how many new patients will get access. The bigger part is arguably once again up to health plans. They will decide how strictly to interpret the FDA’s guidelines, and whether patients will have to jump through hoops to get the medicine. The size of the potential patient population may inspire them to clamp down, cost-effectiveness be damned. The barriers to heart drugs are navigable. Novartis was likely inspired to pay up for Medicines because it managed the feat with its heart-failure treatment Entresto. Sales of the drug started extremely slowly, but are now growing at a respectable clip. There is a clear opportunity in this somewhat neglected space. Profiting from it might require a high risk tolerance and an extra measure of patience. To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
NEW YORK, NY / ACCESSWIRE / November 27, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Tiffany & Co. (NYSE:TIF) The investigation concerns ...
Major benchmarks closed at record highs on Monday, thanks to newfound investor optimism around developments in the U.S.-China trade talks and possible completion of the phase one trade agreement before the year runs out.
NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ:MDCO) The investigation ...
NEW YORK, Nov. 25, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased The Medicines Company (the.
WILMINGTON, DE / ACCESSWIRE / November 25, 2019 / Rigrodsky & Long, P.A.: Do you own shares of The Medicines Company (NASDAQ GS: MDCO )? Did you purchase any of your shares prior to November 24, 2019? ...
NEW YORK, Nov. 25, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: The Medicines Company (NASDAQ: MDCO)The.
(Bloomberg) -- Novartis AG agreed to buy Medicines Co. and its promising heart drug for $9.7 billion, the latest move in the Swiss drugmaker’s push to amass novel treatments for complex conditions.Medicines Co.’s experimental treatment inclisiran uses a new approach to lower bad cholesterol in especially hard-to-treat patients. Novartis Chief Executive Officer Vas Narasimhan was willing to foot the bill, which includes stock options and convertible debt, for a medicine that appears to be moving quickly to the U.S. market where it will compete against existing products from Amgen Inc., Regeneron Pharmaceuticals Inc. and Sanofi.Drugmakers are targeting conditions and technologies that can set them apart from rivals, leaving more room for sales growth and allowing them to charge higher prices in an increasingly cost-conscious market. Narasimhan is adding Medicines Co. to a list of purchases that includes AveXis, maker of the $2.1 million gene therapy Zolgensma, and Endocyte, developer of targeted cancer treatments.The 43-year-old CEO has moved to spin off contact-lens maker Alcon and to ditch a stake in the consumer-health venture with GlaxoSmithKline Plc that makes Panadol painkillers and Theraflu cold remedies.Medicines Co. gives Novartis entry into a realm where at least one drug, Repatha, is forecast to achieve blockbuster status by 2021. Another similar cholesterol treatment, Regeneron and Sanofi’s Praluent, hasn’t fared as well, and prices on both drugs were recently cut as studies questioned their cost-effectiveness.New TechnologyThe medicine at the heart of the Novartis transaction is based on a technology discovered in the last few decades, called RNA interference, which stops cells from making specific proteins. The therapy is injected just twice a year, unlike existing treatments that need to be administered once or twice a month. Should it be approved by regulators, annual sales might reach a peak of $4 billion, according to Peter Welford, an analyst at Jefferies in London.Medicines Co. shareholders will get $85 a share, Novartis said in a statement. That’s a 45% premium to the closing price on Nov. 18, before Bloomberg reported the two companies were in talks.Shares of Parsippany, New Jersey-based Medicines Co. surged as much as 23% in early New York trading. The stock had already tripled in 2019 with anticipation building over the blockbuster potential of inclisiran. Novartis rose 0.7% at 3:40 p.m. Monday in Zurich.Narasimhan is paying a high price for a deal that essentially delivers a single treatment, analysts said.The transaction doesn’t bring a research platform or other significant assets besides inclisiran, said Tim Anderson at Wolfe Research. “For an outlay of $9 billion, it would be nice to have the latter,” he wrote in a note.At Novartis, inclisiran will join a stable of products that includes the heart-failure treatment Entresto. High levels of bad cholesterol, also known as LDL, are a leading cause of heart attacks and millions of people take statin drugs to keep them under control. Novartis is targeting a patient population of around 50 million people, according to a presentation.The medicine could become one of Novartis’s biggest sellers and help boost profit margins in the company’s innovative drugs division to a percentage in the mid- to high-30s in the medium term, Narasimhan said. Medicines Co. plans to submit an application for the drug in the U.S. before year-end.‘Cause for Caution’Recent data on the cholesterol treatment, a partnership with Alnylam Pharmaceuticals Inc., suggest RNA interference will help inclisiran stand out from Repatha and Praluent.The only approved drugs that use the gene-silencing approach come from Alnylam, which licensed rights to inclisiran to Medicines Co. The success of the drug, which has shown few side effects in clinical trials, is good news for Alnylam, whose Onpattro treatment for a rare inherited protein abnormality was the first therapy approved in the field. Givlaari, another one of Alnylam’s RNA products that treats a rare liver disease, was approved last week and will carry an annual U.S. wholesale price of $575,000.“Novartis hopes to leverage its growing cardiovascular might and inclisiran’s differentiated profile,” Bloomberg Intelligence’s Sam Fazeli wrote in a note. “The lackluster performance of drugs targeting the same mechanism from Amgen and Sanofi is cause for caution.”At 11 times consensus 2023 sales, Novartis is paying a high price relative to recent deals, according to Fazeli.Medicines Co.’s drug cleared a key hurdle this summer as a late-stage study showed it cut bad cholesterol levels in half over 18 months. Two years ago, the company said it would lay off most of its workers as it restructured to focus on developing inclisiran.(Updates shares in eighth paragraph.)\--With assistance from Cristin Flanagan and John Lauerman.To contact the reporters on this story: James Paton in London at email@example.com;John Lauerman in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Eric Pfanner at email@example.com, Marthe Fourcade, Anne PollakFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.